Vivani Medical (NASDAQ:VANI) versus Cumberland Pharmaceuticals (NASDAQ:CPIX) Critical Survey

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cumberland Pharmaceuticals and Vivani Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1	0	0	0	1.00
Vivani Medical	1	1	2	0	2.25

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 172.53%. Given Vivani Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Cumberland Pharmaceuticals.

Insider and Institutional Ownership

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Cumberland Pharmaceuticals and Vivani Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52 million	2.58	-$2.84 million	($0.71)	-10.78
Vivani Medical	N/A	N/A	-$26.61 million	($0.35)	-3.93

Cumberland Pharmaceuticals has higher revenue and earnings than Vivani Medical. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500.

Profitability

This table compares Cumberland Pharmaceuticals and Vivani Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Vivani Medical	N/A	-191.05%	-70.91%

Summary

Vivani Medical beats Cumberland Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.